This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2007 Jul:18 Suppl 9:ix87-8.

doi: 10.1093/annonc/mdm299.

Temsirolimus in the treatment of advanced renal cell carcinoma

M E Gore¹

Affiliations

PMID: 17631601
DOI: 10.1093/annonc/mdm299

Free article

Review

Temsirolimus in the treatment of advanced renal cell carcinoma

M E Gore. Ann Oncol. 2007 Jul.

Free article

. 2007 Jul:18 Suppl 9:ix87-8.

doi: 10.1093/annonc/mdm299.

Author

M E Gore¹

Affiliation

¹ Royal Marsden Hospital, Fulham Road, London, UK.

PMID: 17631601
DOI: 10.1093/annonc/mdm299

No abstract available

PubMed Disclaimer

Similar articles

Sorafenib [corrected] in kidney cancer.
Escudier B. Escudier B. Ann Oncol. 2007 Jul;18 Suppl 9:ix90-3. doi: 10.1093/annonc/mdm301. Ann Oncol. 2007. PMID: 17631603 No abstract available.
Temsirolimus (Torisel) for advanced renal cell carcinoma.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2007 Dec 17;49(1276):103-4. Med Lett Drugs Ther. 2007. PMID: 18084154 No abstract available.
Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC.
Figlin RA. Figlin RA. Nat Clin Pract Oncol. 2008 Oct;5(10):601-9. doi: 10.1038/ncponc1173. Epub 2008 Jul 8. Nat Clin Pract Oncol. 2008. PMID: 18607393 Review.
Temsirolimus for advanced renal cell carcinoma.
Figlin RA. Figlin RA. Clin Adv Hematol Oncol. 2007 Nov;5(11):893. Clin Adv Hematol Oncol. 2007. PMID: 18185488 No abstract available.
Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.
Malizzia LJ, Hsu A. Malizzia LJ, et al. Clin J Oncol Nurs. 2008 Aug;12(4):639-46. doi: 10.1188/08.CJON.639-646. Clin J Oncol Nurs. 2008. PMID: 18676330 Review.

See all similar articles

Cited by

A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naïve castration-resistant prostate cancer.
Kruczek K, Ratterman M, Tolzien K, Sulo S, Lestingi TM, Nabhan C. Kruczek K, et al. Br J Cancer. 2013 Oct 1;109(7):1711-6. doi: 10.1038/bjc.2013.530. Epub 2013 Sep 5. Br J Cancer. 2013. PMID: 24008662 Free PMC article. Clinical Trial.
High-Throughput Screening of the Repurposing Hub Library to Identify Drugs with Novel Inhibitory Activity against Candida albicans and Candida auris Biofilms.
Ajetunmobi OH, Wall G, Vidal Bonifacio B, Martinez Delgado LA, Chaturvedi AK, Najvar LK, Wormley FL Jr, Patterson HP, Wiederhold NP, Patterson TF, Lopez-Ribot JL. Ajetunmobi OH, et al. J Fungi (Basel). 2023 Aug 27;9(9):879. doi: 10.3390/jof9090879. J Fungi (Basel). 2023. PMID: 37754987 Free PMC article.
PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects.
Krymskaya VP, Goncharova EA. Krymskaya VP, et al. Cell Cycle. 2009 Feb 1;8(3):403-13. doi: 10.4161/cc.8.3.7555. Epub 2009 Feb 6. Cell Cycle. 2009. PMID: 19177005 Free PMC article. Review.
RLIP76: a target for kidney cancer therapy.
Singhal SS, Singhal J, Yadav S, Sahu M, Awasthi YC, Awasthi S. Singhal SS, et al. Cancer Res. 2009 May 15;69(10):4244-51. doi: 10.1158/0008-5472.CAN-08-3521. Epub 2009 May 5. Cancer Res. 2009. PMID: 19417134 Free PMC article.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information